Rosuvastatin surpasses atorvastatin across full dose range

Rosuvastatin ['Crestor'] is significantly more effective than atorvastatin ['Lipitor'] in reducing LDL-cholesterol levels in patients with hypercholesterolaemia, according to results from a study presented at the 2002 European Society of Cardiology (ESC) congress [Berlin, Germany; August-September 2002]. Furthermore, significantly greater improvements in the levels of non-HDL and total cholesterol, as well as apolipoprotein B levels were observed in rosuvastatin, compared with atorvastatin, recipients across the dose range evaluated. At higher doses, rosuvastatin was shown to provide additional benefit, compared with atorvastatin, through significantly greater increases in HDL-cholesterol and apolipoprotein A-I levels.